Source: Investigational New Drugs. Unidade: FMRP
Subjects: EPIGÊNESE GENÉTICA, MEDULOBLASTOMA, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ANDRADE, Augusto Faria et al. Erratum to: The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma. Investigational New Drugs, v. 35, n. 1, 2017Tradução . . Disponível em: https://doi.org/10.1007/s10637-016-0412-1. Acesso em: 01 out. 2024.APA
Andrade, A. F., Borges, K. S., Suazo, V. K., Geron, L., Corrêa, C. A. P., Castro-Gamero, A. M., et al. (2017). Erratum to: The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma. Investigational New Drugs, 35( 1). doi:10.1007/s10637-016-0412-1NLM
Andrade AF, Borges KS, Suazo VK, Geron L, Corrêa CAP, Castro-Gamero AM, de Vasconcelos EJR, Oliveira RS de, Neder L, Yunes JA, Aguiar S dos S, Scrideli CA, Tone LG. Erratum to: The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma [Internet]. Investigational New Drugs. 2017 ; 35( 1):[citado 2024 out. 01 ] Available from: https://doi.org/10.1007/s10637-016-0412-1Vancouver
Andrade AF, Borges KS, Suazo VK, Geron L, Corrêa CAP, Castro-Gamero AM, de Vasconcelos EJR, Oliveira RS de, Neder L, Yunes JA, Aguiar S dos S, Scrideli CA, Tone LG. Erratum to: The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma [Internet]. Investigational New Drugs. 2017 ; 35( 1):[citado 2024 out. 01 ] Available from: https://doi.org/10.1007/s10637-016-0412-1
